Abiomed Announces Webcast on Clinical Best Practices for Heart Recovery.

Experts Share Experience with AB5000[TM] Circulatory Support System for Heart Recovery and Patient Discharge

DANVERS, Mass. -- Abiomed, Inc. (NASDAQ: ABMD) today announced that on Wednesday, December 13, 2006, at 4 p.m. ET, it will host a webcast and conference call on clinical best practices for heart recovery. The webcast will be offered as part of Abiomed's Partnership in Healthcare Program, and this educational session will provide information on best practices from top hospitals for achieving high recovery rates and favorable outcomes for patients in acute heart failure. Topics will include: establishing hospital protocols; published recovery rates and clinical outcomes at leading heart hospitals; case studies, post-operative management and how to assess heart recovery.

Webcast presenters include:

* Jack Crumbley, M.D., Associate Professor of Surgery at the Medical University of South Carolina, Charleston.

* Elena Ghosh, MSN, CRNP, Ventricular Assist Device (VAD) Nurse Practitioner at Lankenau Hospital, Philadelphia.

* Daniel Raess, M.D., Medical Advisor, Abiomed, Inc.; Former Director of Cardiac Surgery at St. Francis Heart Center, Indiana; Former Attending Surgeon, Indiana Heart Hospital.

* Nadine Brooks, R.N., Clinical Outcomes Manager, Abiomed, Inc.

"We are dedicated to improving outcomes by sharing evidence-based best practices and to establish heart recovery as the standard of care for acute heart failure patients," said Michael R. Minogue, Chairman, CEO and President of Abiomed.

Abiomed has exclusive labeling in the United States for recovery indications through its AB5000 Circulatory Support System and BVS([R]) 5000 Biventricular Support System. The AB5000 provides temporary support for one or both sides of the natural heart in circumstances where the heart has failed, giving the patient's heart the opportunity to rest and potentially recover - and giving surgeons the therapeutic flexibility necessary to determine the best endpoint for treatment. Published results have demonstrated that heart recovery is the most likely outcome for acute heart failure patients when supported with the Abiomed AB5000 and BVS 5000 systems while following established protocols.

WEBCAST AND CONFERENCE CALL INFORMATION

Please register at www.abiomed.com and click on Recovery Best Practices. Those without computer access may listen-in by dialing 800-510-9691 or 617-614-3453 for international callers. A replay of the call will be available on www.abiomed.com.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc., is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. Abiomed currently manufactures and sells the AB5000[TM] Circulatory Support System and the BVS([R]) 5000 Biventricular Support System for the temporary support of all patients with failing but potentially recoverable hearts. The Company also developed the AbioCor([R]) Implantable Replacement Heart. In Europe, Abiomed offers the minimally invasive Impella([R]) Circulatory Support System under CE Mark approval. The Impella([R]) 5.0 and 2.5 are investigational devices limited by Federal Law solely to investigational use in the United States. Other Impella devices are not yet available for sale in the United States. For additional information please visit: www.abiomed.com.

FORWARD-LOOKING STATEMENTS

This Release contains forward-looking statements, including statements

regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.